Advertisement
New Zealand markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6019
    -0.0015 (-0.24%)
     
  • NZD/EUR

    0.5582
    -0.0012 (-0.21%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    78.42
    -0.84 (-1.06%)
     
  • GOLD

    2,375.00
    +34.70 (+1.48%)
     
  • NASDAQ

    18,149.15
    +35.69 (+0.20%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,473.96
    +86.20 (+0.22%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7820
    +0.0140 (+0.01%)
     

Teva Pharmaceutical’s Performance in the Third Quarter

Teva Pharmaceutical’s Performance in the Third Quarter

In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.